Results 41 to 50 of about 46,900 (298)

Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis

Journal of Nepal Health Research Council, 2021
Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya, Bhojraj Adhikari, Manisha Bhochhibhoya, Shweta Nakarmi   +3 more
doaj   +1 more source

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, EarlyView.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

Senescent Cell Derived Artificial Vesicle‐Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross‐Presentation Efficacy

Advanced Science, EarlyView.
A senolytic sonovaccine platform (SenoVac) is developed, in which senescent cell‐derived vesicles serve as broad senescent cell antigen reservior. The “2‐step” click chemistry strategy for effective lymph node delivery, and ultrasound‐triggered endosomal escape to boost cross‐presentation, ensures efficient senescent cell clearance and disease ...
Liang Zhang, Yubo Lai, Jia Wang, Lingling Liu, Jieyuan An, Mi Qu, Yuan Liang, Bijun Tan, Guodong Yang, Xuekang Yang, Lijun Yuan   +10 more
wiley   +1 more source

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

Терапевтический архив
The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group.
Iuliia G. Samoilova, Olga E. Vaizova, Anastasia E. Stankova, Mariia V. Matveeva, Daria V. Podchinenova, Dmitry A. Kudlay, Anastasiia A. Borozinets, Tatyana A. Filippova, Ivan R. Grishkevich, Anastasia V. Partala, Diana A. Gerasimova   +10 more
doaj   +1 more source

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors

Сахарный диабет, 2020
Hyperuricemia is an increase of uric acid (UA) concentration in blood serum >420 pmol/L in men or >360 pmol/L in women and is considered to be a common biochemical abnormality. This condition shows that the extracellular fluid is oversaturated with
Taras S. Panevin, Olga V. Zhelyabina, Maxim S. Eliseev, Marina V. Shestakova   +3 more
doaj   +1 more source

SuFEx‐Enabled Reprogramming of Flavonoids for Selective α‐Glucosidase Covalent Inhibition

Advanced Science, EarlyView.
Selective inhibition of intestinal α‐glucosidase remains limited by poor enzyme specificity and off‐target metabolic effects. Here, SuFEx click chemistry is used to reprogram natural flavonoids into covalent inhibitors with enhanced α‐glucosidase selectivity and controlled reactivity. This strategy enables effective regulation of carbohydrate digestion
Fengyu Guo, Liwei Zhang, Minlong Wang, Yanjin Du, Tianyu Zhang, Hao Chen, Jiazeng Sun, Yang Yu, Zude He, Jie An, Xiaoxu Zhang, Weilin Lin, Fazheng Ren, Pengjie Wang, Ping Liu   +14 more
wiley   +1 more source

The study of a new and specific proline cleaving peptidase from bovine serum [PDF]

, 2003
Prolyl oligopeptidase is a serine peptidase characterised by oligoendopeptidase activity. Definitive evidence for the discrete biological role of prolyl oligopeptidase remains unknown, though its role in the maturation and degradation of peptide hormones
Collins, Patrick
core  

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees

Journal of Obesity & Metabolic Syndrome, 2017
Background : Dipeptidyl peptidase-4 (DPP-4) is an aminopeptidase that inhibits the enzymatic degradation of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptides, neuropeptides, and various chemokines.
Ji Yeon Lee, Byoung Kuk Jang, Min Kyung Song, Hye Soon Kim, Mi-Kyung Kim   +4 more
doaj   +1 more source

Animal models of idiopathic membranous nephropathy: Recent advances and future perspectives

Animal Models and Experimental Medicine, EarlyView.
This review focuses on the evolution of idiopathic membranous nephropathy (IMN) animal models from traditional approaches (Heymann nephritis, C‐BSA, APA) to antigen‐specific models (PLA2R, THSD7A), critically evaluating their advances and limitations in replicating human IMN pathology.
Qiuying Liu, Huixian Bian, Jianhua Liu, Lina Wu, Zhijie Zhang, Hongli Zhao, Xiaosong Qin   +6 more
wiley   +1 more source

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source